Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

USA - NASDAQ:SXTP - US83006G4010 - Common Stock

1.34 USD
-0.02 (-1.47%)
Last: 11/3/2025, 8:00:01 PM
1.35 USD
+0.01 (+0.75%)
After Hours: 11/3/2025, 8:00:01 PM
Fundamental Rating

2

SXTP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. SXTP has a bad profitability rating. Also its financial health evaluation is rather negative. SXTP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
SXTP had a negative operating cash flow in the past year.
SXTP had negative earnings in each of the past 5 years.
SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP has a worse Return On Assets (-198.65%) than 88.54% of its industry peers.
With a Return On Equity value of -342.13%, SXTP is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 63.74%, SXTP is in the better half of the industry, outperforming 72.40% of the companies in the same industry.
SXTP's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
SXTP has a worse debt/assets ratio than last year.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -18.10. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SXTP (-18.10) is worse than 81.77% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that SXTP is not too dependend on debt financing.
SXTP has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: SXTP outperforms 51.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -18.1
ROIC/WACCN/A
WACC8.85%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.27 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a Current ratio (2.27) which is comparable to the rest of the industry.
A Quick Ratio of 1.80 indicates that SXTP should not have too much problems paying its short term obligations.
SXTP has a Quick ratio (1.80) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.8
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SXTP have decreased strongly by -512.57% in the last year.
The Revenue has grown by 120.64% in the past year. This is a very strong growth!
SXTP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.49% yearly.
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%

3.2 Future

The Earnings Per Share is expected to grow by 25.73% on average over the next years. This is a very strong growth
SXTP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 82.46% yearly.
EPS Next Y94.26%
EPS Next 2Y36.27%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.27%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (11/3/2025, 8:00:01 PM)

After market: 1.35 +0.01 (+0.75%)

1.34

-0.02 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/dmh
Earnings (Next)N/A N/A
Inst Owners11%
Inst Owner Change0%
Ins Owners1.2%
Ins Owner Change0.44%
Market Cap5.49M
Revenue(TTM)973.70K
Net Income(TTM)-8307500
Analysts80
Price Target7.14 (432.84%)
Short Float %0.65%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.98%
Min EPS beat(2)-27.66%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-80.11%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)1
Avg EPS beat(8)-42.74%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.66%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)0.28%
Revenue beat(4)1
Avg Revenue beat(4)-19.46%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)0.28%
Revenue beat(8)1
Avg Revenue beat(8)-27.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-45.78%
EPS NQ rev (3m)-45.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.64
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-21.66
EYN/A
EPS(NY)-5.47
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0.24
BVpS0.59
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 145.9%
Cap/Sales 10.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.8
Altman-Z -18.1
F-Score3
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
EPS Next Y94.26%
EPS Next 2Y36.27%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y13.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A

60 DEGREES PHARMA INC / SXTP FAQ

What is the fundamental rating for SXTP stock?

ChartMill assigns a fundamental rating of 2 / 10 to SXTP.


Can you provide the valuation status for 60 DEGREES PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to 60 DEGREES PHARMA INC (SXTP). This can be considered as Overvalued.


What is the profitability of SXTP stock?

60 DEGREES PHARMA INC (SXTP) has a profitability rating of 1 / 10.


What is the expected EPS growth for 60 DEGREES PHARMA INC (SXTP) stock?

The Earnings per Share (EPS) of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 94.26% in the next year.